We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Avacta Group Plc | AVCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.75 | -3.52% | 48.00 | 14:40:26 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 49.75 | 47.75 | 49.75 | 48.00 | 49.75 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 11/4/2024 15:26 by jaknife jacktrax,"Taking part in that placing Jak , the one for existing shareholders , so you held shares Jak , give me the clever words and shoot me down but I think you are telling porkies" The placing was open to any professional investor. You didn't need to be a shareholder to participate. If you read the original placing RBS, for example, you will find the words: "The Placing will be conducted through an accelerated bookbuild (the "Bookbuild") which will be launched immediately following this announcement (being, together with the Appendices hereto, this "Announcement") and will be made available to new and existing institutional investors." [my bold] see: JakNife |
Posted at 28/3/2024 09:40 by ohwhatfun The majority of AIM companies are set up by fraudsters looking to pocket £250k salary per year, free shares plus reload on options.Which brings me to AVA/ALS 6000/3996 which were ARI 6000/3996 being pursued in the US by Arisaph, in collaboration with Tufts. Even with the co founder worth $2 Billion, high hopes, targets to progress identified re safety and expecting material efficacy. It was all abandoned, the supposed holy grail prodrug abandoned by very wealthy people. Post abandoned, Arisaph staff appear at Avacta, AVA6000/3996 appears, then a link up with Tufts. Great story to the ignorant who didn’t try to make or accept the link. Fantastic spin to suck in investors. No mention by the pump crew that it’s a regurgitated US abandoned failure. Some staff that came from Arisaph and pumped in an RNS have now gone (but no news about them going). It’s a high risk previous failure abandoned by wealthy backers. It was a follow the money game, and no doubt some saw sense and took profits high up. Others unfortunately lost out, on reading very poor amateur research notes which ignored the US copycat failure, and recorded some highly naive info, post phase 1 safety expectations, EG big pharma, big up front payments, will fund phase 2, complete nonsense. Then, astoundingly, out came a pump, to boost the share price whilst a 50p raise was in play. Did they know, did they sell into the buyer volume. It’s been done plenty of times. You think they had no idea, highly unlikely. You are dealing with good honest city traders. Worthy of a viz character name. Today the honest city trader says buy ice in Antarctica as it’s disappearing fast. |
Posted at 26/3/2024 18:47 by ohwhatfun Avacta stuck out like a sore thumb, flying high in a market where promising ideas have been destroyed. Many diluted into oblivion or now bust.The Avacta crazy market cap was down to a long run of excessive pumping by Myles and co, to a retail army oblivious to/stubborn ignorance of the risks. A fund raise was nailed on and at significant discount, a plethora of small caps have followed the same fate. It was blatantly obvious what was coming but due the fantasy forecasts in notes by the pumpers along with a social media frenzy, ably assisted by the CEO, private investors got mugged. The blame lies entirely with the fantasy crew, completely ignoring the obvious, including positive posts, dragging in buyers, just before the guillotine fell. Investors thought the pumpers had inside information, raise not coming, ignore the warnings. This remains very high risk, and will do for quite some time. The pumping frenzy simply offered an opportunity for some to go short, who anticipated, with good reason, that a heavily discounted raise would come. It did, they were right, believed favoured pump crew, wrong. That’s about it, stop trying to deflect the reality, the CEO and pump crew sucked in buyers, and stiffed them good and proper. |
Posted at 21/3/2024 14:19 by stmcn TBH - the RNS sounds just like another BS Smith ‘no news’ note. Pointless issuing it and just riles the LTH’s as Avacta seemingly unable to close out P1a and that continues to drag with no commitment on exit into P2. Needs a CEO change, as Smith cannot manage a plan and clearly cannot manage commercial deals/finances/inves |
Posted at 02/3/2024 09:46 by rajraj b Also, thank you for clarifying that the new institutional investors are AJ Bell, Interactive Investor and Hargreaves Lansdowne in the capacity as holding accts. Seems strange that AS would want to fool/mislead people that way. That's very deceitful if that's the case. Or maybe there could be some real II involved? Can't remember what the minimum holding is required before a TR1 is needed. |
Posted at 02/3/2024 09:24 by pwhite73 Rajraj b - I'm so relieved to know you are still with us and haven't gone and done anything silly.You ask - "I would like to know who the significant institutional investors and European Healthcare fund" All shares are placed with institutions. Unless you're buying the shares direct from the company you will buy the shares through an institution. On 28/02/2024 they told you which institutions would participate in the REX Retail Offer. RNS 28/02/2024 - "At the time of this announcement the following intermediaries have confirmed their participation in the REX Offer: - AJ Bell · Hargreaves Lansdown · interactive investor" Do you recognise any of those names?. So unless a TR1 is issued the institutions are the usual nominated brokers for PIs. As for the European Healthcare Fund again totally misleading. There are millions of health care funds out there. What matters is if they took the placing shares at 50p and held onto them hence a TR1 is issued or they took the placing shares at 50p and forward sold them them to PIs. In short if there are no TR1s to follow the placing then all the placing shares issued are with PIs. |
Posted at 28/2/2024 09:58 by loglorry1 Not speculation look at the top holders. Not a single one is a specialist biotech fund:-Conifer Management LLC Hedge Fund Baillie Gifford & Co. Investment Advisor Edinburgh Worldwide Investment Trust plc Mutual Fund Baillie Gifford Global Discovery Fund Mutual Fund Hughes (Robert Anthony) Individual Investor Kamani (Umar Mahmud) Individual Investor Unicorn Asset Management Ltd. Investment Advisor Avacta Group Plc Employees' Share Trust Corporation Premier Asset Management Ltd Investment Advisor/Hedge Fund Robbins (Sheldon Bryan) Individual Investor |
Posted at 21/2/2024 10:13 by ohwhatfun LogSome points. Avacta is far too early in process (trials) to attract backers, the numbers involved are too low. Hence that is a very slim chance event. Even then it appears increased doses failed to meet the same standard as the original Dox, safety up efficacy not. Not an efficacy trial they say, safety, but it's sample of efficacy regardless of the phase 1 label. There are a host of phase 1 safety trials where efficacy has been better than the standard of care. April, Bond. I'm trying to get my head around the bond, your April comment, floor reset 18 months, the lower limit appears to be 95p But then it states "save in limited circumstances there is a reset price floor of 95p" No explanation of that, but I guess the limited circumstances relate to share price performance (EG 95p breached), so that floor of 95p is likely to drop, potentially materially. The bond can also convert partially at any time at the bond holders discretion. As is typical, the full details about the bond are not in there. Always fun to see negativity thrown at warning posts about how vicious the city can be when it comes to fund raise time. Pure tunnel vision by the city vultures, crash it as much as possible to maximise returns, they don't give a damn about the company. Private investors seem to fight against what is blatantly obvious, a hope that some Good Samaritan will appear with the cash, ignoring the likely discounted fund raise reality. Fingers crossed there are not too many private investors geared beyond their means, there are always some, and no doubt sleepless nights already in play. I do not wish those crash events on them, it's vile, they get wiped out, the city does not care, it's just another successful day at the office to them, |
Posted at 19/2/2024 09:28 by loglorry1 I have no clue if their story holds up and unless you have a PhD and a lot of experience in the exact field nor do you. I very much doubt anyone on this board has the expertise to evaluate their claims and probably none of the private investors that hold the shares does either. Even if they did they wouldn't have access to the data required to evaluate their claims.There are no peer reviewed independently funded papers of their claims either which is a red flag for me. The company engages in a massive amount of financial PR targeted at private investors another red flag. Saying all that if enough people believe and buy the shares the share price will go up. From what I know of your posts on CINE PWhite, your analysis of these situations isn't much good either. Do you have the experience and relevant data to provide input on the science? From what I can tell of @tickboo is that he buys story stocks. I don't think he has any track record of success but like everyone he might have got a bit lucky here and there. He probably sold a lot of his holding much higher but he'll never admit it. |
Posted at 11/1/2024 11:54 by ohwhatfun The pointArispah US, they were working on ARI-6000 which is ARA-6000 ARI 6000 was to go into phase 2 in the US but didn't, the factor noted was a requirement of 1000% reduction in side effects to progress. Clearly Arisaph didn't go ahead, and disappeared. They had people there, one of which banked $2 billion in another company, so the money/backers were there. Arisaph seems to have folded around early 2018, going by names attached to the company, moving on. One such name is Dr Matthew Vincent who appeared at Avacta in October 2017. It seems pretty clear Dr Vincent then talked Avacta into taking on the abandoned prodrug in the US ARI-6000. No surprise then when Avacta announce a collaboration has agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston. Which happens to be exactly the same company/person who was working with Arispah on ARI-6000 AKA AVA6000. Abandoned in the US, with very wealthy backers, but somehow a game-changer in the UK. It doesn't make any sense, why was a 1000% improvement on safety required to make it viable to go to phase 2 in the US. As it didn't progress I can only guess the targets were not hit and trials were abandoned. So that for me is a big question, interesting science but you have an army of private investors sucked in by the covid tests, which drove up the share price, they are now clinging onto AVA6000 as the saviour. In this current market Avacta has an uncomfortable market cap, add it the excitement surrounds an apparently abandoned US project, where such things attract a much greater interest and backing. AVA6000 appears to be a recycled failure in the US, same people involved that have encouraged Avacta to take it on, using UK investors money. The safety factor figure is obviously relevant on the point of progression or abandonment, as other companies in the prodrug sector quote the safety factor improvement. So there appears to be a lot of questions unanswered. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
